David Lane (oncologist)
Professor Sir David Philip Lane is the Chief Scientist of the Agency for Science, Technology and Research (A*STAR). He is also the Scientific Director of the Ludwig Institute for Cancer Research and Chairman of Chugai Pharmabody.
Sir David completed his undergraduate and postgraduate degrees at University College, London where he studied auto-immunity under the supervision of Avrion Mitchison. He carried out Post Doctoral Research first at the Imperial Cancer Research Fund (ICRF) in London with Lionel Crawford and then at the Cold Spring Harbor Laboratory in New York with Joseph Sambrook. On returning to the UK, Sir David set up his own laboratory with Cancer Research Campaign (CRC) funding at Imperial College, London, then moving to the ICRF laboratories at Clare Hall before moving in 1990 to Dundee to help establish the CRC laboratories there.
Sir David has published more than 350 research articles that have been citied over 39,000 times and is internationally recognised for his original discovery of the p53 protein SV40 T antigen complex and for his many subsequent contributions to the p53 field. The p53 gene is the most frequently altered gene in human cancer with more than half of all cancers having mutant p53. He is co-author with Ed Harlow of the most successful practical guide to the use of immunochemical methods. The "Antibodies" manual has sold over 40,000 copies.
Sir David is a member of the European Molecular Biology Organization (EMBO), and in 1996 was elected a Fellow of the Royal Society, the UK's premier Academy. He is also a Fellow of the Royal Society of Edinburgh, the Royal College of Pathologists, the Royal College of Surgeons of Edinburgh and a founder member of the Academy of Medical Sciences. He has won many international prizes for his work including the Joseph Steiner Prize, the Meyenburg Prize (1995), the Yvette Mayent Prize and the Paul Ehrlich Prize. He has been awarded honorary degrees from the Universities of Toulouse, Birmingham, Aberdeen, Stirling, Abertay and Nottingham. He has also been recognized for his business acumen with the award of Emerging Entrepreneur of the year.
He has played an active part in UK science, sitting at various times on the Scientific Committee of the CRC, the Cell Board of the MRC and briefly on the council of the ICRF. Sir David founded the Dundee based Biotechnology company, Cyclacel Ltd. and was the Chief Scientific Officer from 1996 - 2004. From 2004 - 2007, he was the Executive Director of the Institute of Molecular & Cell Biology (IMCB) in Singapore. He is dedicated to the successful translation of research for patient benefit and participated in the early discussions around the scientific benefits of the merger of ICRF and CRC.
Sir David is well known for his speaking to non-specialist groups and for his clarifying reviews, of which his commentary "p53, guardian of the genome" published in Nature, is a key example.
David Lane was knighted for his contribution to cancer research in the New Year honours list in January 2000.
|This United Kingdom biographical article related to medicine is a stub. You can help Wikipedia by expanding it.|